News | Contrast Media | August 15, 2017

New clinical and research guidelines urge caution when using gadolinium-based contrast, which evidence suggests can accumulate in the brain

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

August 15, 2017 — The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast agents during MRI scans. Emerging research suggests gadolinium-based contrast agents, injected in a patient's veins to brighten tissues in MRI images, accumulate in the brain. More than 300 million doses of such drugs have been administered since their introduction in 1987.

"Small amounts of gadolinium deposit in certain parts of the brain in people who undergo repeated gadolinium-based contrast agent enhanced exams," said Vikas Gulani, M.D., Ph.D., associate professor of radiology, urology and biomedical engineering at Case Western Reserve University School of Medicine, member of the Case Comprehensive Cancer Center, and director of magnetic resonance imaging at University Hospitals Cleveland Medical Center. "The ISMRM response is a review of the literature and a series of recommendations on what the community ought to do in response to this phenomenon." Gulani helped craft the new recommendations and served as first author for the review, featured on the cover of The Lancet Neurology.

In the review, Gulani and other experts suggest if gadolinium is not needed for a particular exam, it should not be administered. A risk-benefit analysis should happen for all exams. "Nearly everyone needs an MRI scan at some point, often contrast enhanced," Gulani said. "The idea that some gadolinium could be depositing in the brain is disconcerting to patients. In that situation, putting the risk and benefits into context is important." If gadolinium is needed, it should be administered and the choice of agent is dependent on a large number of factors, only one of which is the deposition phenomenon.

Defining harm is an important consideration. Gadolinium-based contrast agents have a proven track record for accurate diagnosis and treatment monitoring of a large number of diseases including cancer, neurological pathology, heart disease, liver disease, and many other important conditions afflicting adults and children. They are associated with few side effects, the most serious of which are extremely infrequent and affect already sick patients with severe kidney failure. The new review does not suggest sweeping changes in the use of MRI contrast agents, as at present, there is no evidence linking the brain deposits to health risks. However, it provides clarity about the previously unknown phenomenon of gadolinium deposition in the brain and provides guidance for future research.

For more information: www.thelancet.com/neurology

Related Content

News | Contrast Media

May 19 2022 — Recent disruptions in a pharmaceutical supply chain have impacted the global availability of GE Healthcare ...

Time May 19, 2022
arrow
News | Contrast Media

May 18, 2022 —According to ARRS’ American Journal of Roentgenology (AJR), to ensure that patients with emergent or life ...

Time May 18, 2022
arrow
News | Contrast Media

May 13, 2022 — The ACR Committee on Drugs and Contrast Media, within the ACR Commission on Quality and Safety, is aware ...

Time May 13, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

May 13, 2022 — Alzheimer’s disease is the most common form of dementia, one of the major causes of dependency and ...

Time May 13, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

May 10, 2022 — At the ISMRM 2022 conference, Bruker announced the launch of innovative 7 Tesla and 9.4 Tesla conduction ...

Time May 10, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

May 9, 2022 — At the International Society for Magnetic Resonance in Medicine (ISMRM) 2022 Annual Meeting, GE Healthcare ...

Time May 09, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

May 9, 2022 — For some sports such as tennis, the wrist is frequently under stress, and an injury to the wrist can ...

Time May 09, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

May 9, 2022 — Royal Philips, a global leader in health technology, announced it has received FDA 510(k) clearance for ...

Time May 09, 2022
arrow
News | Radiology Imaging

May 5, 2022 — Significant imaging findings (cancer, infection, pseudoaneurysm, fracture, bowel perforation) can occur in ...

Time May 05, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

May 3, 2022 — More than 60 million magnetic resonance imaging (MRI) scans are performed worldwide each year, but imaging ...

Time May 04, 2022
arrow
Subscribe Now